re selective data disclosure - the irony is that the one issue I would have really liked more clarity on was related to those few patients requiring procedures and the nature/timing of the bleeding pattern once drug is discontinued. to that end the cc actually addressed some of these issues and clarified some of these outstanding issues actually
outside of that I can't think of any possible surprises in the data that could tarnish the approvability of the drug. I just can't
With all due respect Dew, that sounds kinda like a Jonathan Aschoff report on DNDN. Chuck all the mud that you can at em and pray to God that something sticks. There's absolutely no evidence to suggest that JP is being untruthful - just some female-like intuition. That's just not good enough.
PS - for BSR subscribers, I thought Miller explained away the IND FUD perfectly
Market Data 
Markets 
AI
